Severe Acute Respiratory Syndrome(SARS) Therapeutics
Market
Severe Acute Respiratory Syndrome(SARS)
Therapeutics Market Scope: Industry Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size and Growth
The Severe Acute Respiratory Syndrome (SARS) therapeutics market is characterized by evolving treatment strategies and increasing research investments. The market size is projected to reach approximately $500 million by 2026, driven by rising public health initiatives and advancements in antiviral drug development, alongside increased preparedness for potential outbreaks.
Request Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ CEL-SCI Corporation
◍ GeneCure LLC
◍ Humabs BioMed SA
◍ Inovio Pharmaceuticals, Inc.
◍ Nanotherapeutics, Inc.
◍ Novavax, Inc.
◍ Phelix Therapeutics, LLC
◍ Protein Sciences Corporation
The SARS therapeutics market features companies like CEL-SCI, GeneCure, Humabs, Inovio, Nanotherapeutics, Novavax, Phelix, and Protein Sciences. These firms advance vaccine and antiviral development to combat SARS, enhancing market growth through innovative solutions. Sales figures include Novavax with $1.75 billion (2021) and Inovio’s $51 million (2022).
Request Sample Report
Market Segmentation
By Application
Hospital
Clinic
Research Center
By Product
◍ CEL-1000
D-3252
FDX-000
INO-4500
LCA-60
Others
Request Sample Report
Market Growth
Request Sample Report
$ X Billion USD
